A randomized, double-blind, multi-centre, parallel-group study comparing the tolerability and efficacy of moclobemide and dothiepin hydrochloride in depressed patients in general practice

Beaumont, G; Gringras, M; Hobbs, F. D. R.; Drury, V. W. M.; Freeling, Paul; Tylee, André; Shanley, D. F.; Comber, Harry; Little, S.; Hill, Stanley

doi:10.1097/00004850-199300730-00007

Cited by 9 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies used clomipramine (Anafranil) as the comparator (Kragh-Sorensen et al 1995;Larsen et al 1991;Lecrubier and Guelfi 1990), two studies each used amitriptyline (Elavil) (Bakish et al 1992c;Kusalic et al 1993) or maprotiline (Gachoud et al 1994;Steinmeyer et al 1993), and one each compared MOC with isocarboxazid (Marplan) (Larsen et al 1991), fluvoxamine (Luvox) (Bougerol et al 1992), amineptine (Macher and Mirabaud 1992), doxepin (Sinequan) (Philipp et al 1993), or dothiepin (Beaumont et al 1993). Meta-analysis of Abbreviations: IMI ϭ imipramine; MAP ϭ maprotiline; LI ϭ lithium; TCP ϭ tranylcypromine.…”

Section: Outpatient Studies: Moc Versus Active Comparatorsmentioning

confidence: 99%

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Lotufo-Neto

1999

Neuropsychopharmacology

140

View full text Add to dashboard Cite

Section: Outpatient Studies: Moc Versus Active Comparatorsmentioning

confidence: 99%

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Lotufo-Neto

1999

Neuropsychopharmacology

140

View full text Add to dashboard Cite

“…The incidence of AEs and patient withdrawal rates observed in our study were fewer than those reported with short-term use of dosulepin in other studies. 32,33,35,36 Overall, in our study, dosulepin was found to be well-tolerated, with >80% of patients reporting good to excellent tolerability. Dosulepin has not been associated with cardiotoxicity at therapeutic doses.…”

Section: Discussionmentioning

confidence: 56%

Effectiveness and tolerability of eight-week treatment with dosulepin hydrochloride in patients with major depressive disorder not responding to four consecutive weeks of treatment with single selective serotonin reuptake inhibitor

Kumar¹,

Pattojoshi²

2021

Int J Adv Med

View full text Add to dashboard Cite

Background: Though manageable, major depressive disorder remains an underdiagnosed and undertreated condition. The objective of this study was to assess the effectiveness and safety of 8 weeks of treatment with the tricyclic antidepressant dosulepin hydrochloride in patients with depressive episodes not responsive to 4 consecutive weeks of treatment with a single selective serotonin reuptake inhibitor (SSRI).Methods: Patients diagnosed with depressive episode without psychotic symptoms (by ICD-10 diagnostic criteria for research), mini-mental state examination score of ≥24, and not responsive to four weeks of treatment with SSRIs (<50% reduction in depressive symptoms) were enrolled. The main outcome measures were mean change in the Hamilton depression, Hamilton anxiety, and insomnia severity index scores at Week 8 compared to baseline. Adverse events were recorded for safety assessment.Results: A total of 94 patients were enrolled, of which, 90 (95.7%) patients completed the study. Compared to baseline, 8 weeks of treatment significantly changed the HAM-D score by -12.7 (p<0.0001), HAM-A score by -8.3 (p<0.0001), and ISI score by -10.5 (p<0.0001). One patient reported anemia and was withdrawn from the study. Dry mouth and insomnia followed by headache, blurred vision, and drowsiness were the most commonly reported side effects as measured with the antidepressant side-effects checklist. Most side effects were of mild intensity and were related to study medication.Conclusions: Eight weeks of treatment with dosulepin hydrochloride resulted in significant and clinically relevant improvements in depression, anxiety, and insomnia symptoms in Indian patients with MDD.

show abstract

“…A smaller 6 week-trial confirmed the therapeutic equality of doxepin and moclobemide (147). In a large multi-center study involving patients in general practice dothiepin was reported to have a small, but significant advantage over moclobemide in the treatment of depression (24).…”

Section: Other Tri-and Heterocyclicsmentioning

confidence: 99%

Moclobemide: Therapeutic Use and Clinical Studies

Bonnet¹

2003

CNS Drug Reviews

201

100

View full text Add to dashboard Cite

Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied in anxiety disorders. Nearly all meta-analyses and most comparative studies indicated that in the acute management of depression this drug is more efficacious than placebo and as efficacious as tricyclic (or some heterocyclic) antidepressants or selective serotonin reuptake inhibitors (SSRIs). There is a growing evidence that moclobemide is not inferior to other antidepressants in the treatment of subtypes of depression, such as dysthymia, endogenous (unipolar and bipolar), reactive, atypical, agitated, and retarded depression as with other antidepressants limited evidence suggests that moclobemide has consistent long-term efficacy. However, more controlled studies addressing this issue are needed. For patients with bipolar depression the risk of developing mania seems to be not higher with moclobemide than with other antidepressants. The effective therapeutic dose range for moclobemide in most acute phase trials was 300 to 600 mg, divided in 2 to 3 doses. While one controlled trial and one long-term open-label study found moclobemide to be efficacious in social phobia, three controlled trials subsequently revealed either no effect or less robust effects with the tendency of higher doses (600 -900 mg /d) to be more efficacious. Two comparative trials demonstrated moclobemide to be as efficacious as fluoxetine or clomipramine in patients suffering from panic disorder. Placebocontrolled trials in this indication are, however, still lacking.A relationship between the plasma concentration of moclobemide and its therapeutic efficacy is not apparent but a positive correlation with adverse events has been found. Dizziness, nausea and insomnia occurred more frequently on moclobemide than on placebo. Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri-or heterocyclic antidepressants. Gastrointestinal side effects and, espe-97

show abstract

A randomized, double-blind, multi-centre, parallel-group study comparing the tolerability and efficacy of moclobemide and dothiepin hydrochloride in depressed patients in general practice

Cited by 9 publications

References 0 publications

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Effectiveness and tolerability of eight-week treatment with dosulepin hydrochloride in patients with major depressive disorder not responding to four consecutive weeks of treatment with single selective serotonin reuptake inhibitor

Moclobemide: Therapeutic Use and Clinical Studies

Contact Info

Product

Resources

About